⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRVO News
CervoMed Inc. Common Stock
CervoMed to Participate in Upcoming Investor Conferences
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
globenewswire.com
CRVO
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
globenewswire.com
CRVO
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
globenewswire.com
SCYX
CRVO
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
globenewswire.com
CRVO
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
globenewswire.com
CRVO
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
globenewswire.com
CRVO
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
globenewswire.com
CRVO
CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
globenewswire.com
CRVO